Open track

In programme
76 sessions 262 presentations
View the programme

About

This track is co-produced by the European Union Drugs Agency (EUDA).

It welcomes submissions on topics related to addictive behaviours that may not fall within the specific focus of the other co-produced tracks.

Sessions

Wednesday, 23 October

09:30

Official opening

to
Auditorium I
Plenary session

10:00

Meeting the needs of service users and service providers

Plenary session 1

to
Auditorium I
Plenary session

11:50

Advances in drug treatment

to
Auditorium II
Oral presentation session

Innovative health approaches

to
Auditorium III
Oral presentation session

Sex, gender and diversity in drugs

to
Auditorium IV
Oral presentation session

Advancing addiction research: global perspectives and collaborative initiatives

to
Auditorium VI
Oral presentation session

Prevalence of opioids and related harms

to
Auditorium VIII
Oral presentation session

Support for recovery

to
Room 1.07
Short communication session

Alcohol: policy and harm reduction

to
Room 1.08
Short communication session
Closed session

ECR Programme — Scientific writing

to
Room 1.10
Workshop

Evaluation of drug consumption rooms: guidance step by step

to
Room 1.15
Workshop

14:20

Legal shifts and their Impact on drug use and sentencing

to
Auditorium IV
Oral presentation session

Gender and substance use

to
Auditorium VIII
Oral presentation session

Meetings the needs of women who use drugs or alcohol

to
Room 1.06
Short communication session

Methods and measurement

to
Room 1.08
Short communication session

16:00

The recovery journey

to
Auditorium III
Oral presentation session

The growing threat of synthetic drugs – developments and responses in North America and Europe

to
Auditorium VIII
Oral presentation session

Inequalities and needs of migrant groups

to
Room 5C
Oral presentation session

Problematic gambling and gaming

to
Room 1.07
Short communication session

Conceptualising health and harms

to
Room 1.08
Short communication session

17:50

Strengthening quality in substance use disorders treatment

to
Auditorium II
Oral presentation session

NPS: trends, concerns and response strategies

to
Auditorium III
Oral presentation session

Psychedelics 1

to
Auditorium VIII
Oral presentation session

Opioid treatment 1

to
Room 5B
Oral presentation session

Motivations for use

to
Room 5C
Oral presentation session

Opioids: trends, use and treatments

to
Room 1.06
Short communication session

Capacity-building through competencies for the substance use workforce

to
Room 1.10
Workshop

19:30

Why are we not doing better at reducing drug-related deaths?

to
Auditorium I
Big debate

Thursday, 24 October

10:00

Synthetic opioids and psychedelics: new opportunities & new challenges for clinical practice

Plenary session 2

to
Auditorium I
Plenary session

Expert knowledge elicitation to complement and enhance data collection and monitoring efforts.

to
Room 1.10
Workshop

Workshop on conducting drug research in prison: Challenges and key recommendations from the European experience

to
Room 1.15
Workshop

11:50

Opioid treatment 2

to
Auditorium III
Oral presentation session

Evidence informed drug and alcohol policy

to
Auditorium VI
Oral presentation session

Emerging drug harms, DCRs and other responses

to
Auditorium VII
Short communication session

Innovative methods for understanding drug markets and policy

to
Room 5A
Oral presentation session

Challenges, threats, and opportunities in addiction publishing today

to
Room 1.05
Oral presentation session

Natural language processing for addiction research: a practical primer

to
Room 1.06
Workshop

EU research funding opportunities

to
Room 1.07
Workshop

Contemporary issues

to
Room 1.08
Oral presentation session
Closed session

ECR Programme — An introduction to theory in qualitative research

to
Room 1.10
Workshop

14:20

Novel neurobiology - cannabis, cognition and craving

to
Auditorium III
Oral presentation session

Nitazene-related fatal and non-fatal toxicity in Europe: hospital emergency perspective

to
Auditorium VIII
Oral presentation session

Public health and safety impacts of cannabis legalization in Canada: five years in review

to
Auditorium IV
Oral presentation session

Pregnancy, drug use and care

to
Room 5B
Oral presentation session

Women's realities of drug use

to
Room 1.08
Oral presentation session

Scenarios for the future of addictions fields by 2040

to
Room 1.10
Workshop

Writing for 'addiction' journals for early career researchers with DEPP Editors-in-Chief

to
Room 1.15
Workshop

16:00

NPS: Pharmacological Characterization and Substance Analysis

to
Auditorium III
Oral presentation session

A unique care model for inpatient addictions and tri-morbidity within an acute UK hospital

to
Room 5C
Oral presentation session

From genes to brains

to
Room 1.06
Short communication session

Drug trends: experiences from Brazil, the Netherlands, Portugal, and Spain

to
Room 1.08
Oral presentation session

How to respond to real-time drug alerts in European countries ?

to
Room 1.15
Workshop

17:50

Mixed methods for understanding drug use

to
Auditorium III
Oral presentation session

Misuse of medicines

to
Auditorium VIII
Oral presentation session

Hospital-based treatments

to
Room 5B
Oral presentation session

From old to new: changes in drug use

to
Room 5C
Oral presentation session

ScaleUp: Options for scalable psychosocial and pharmacological treatment of stimulant use disorder

to
Room 1.08
Oral presentation session

Toolkit to Deal with Female Drug User Victims of Gender-Based Violence

to
Room 1.15
Workshop

How can the voices of people with lived experience, clients and communities impacted by drug use better inform clinical practice, research and the policy agenda?

to
Auditorium I
Big debate

18:50

EUDA presentation

to
Auditorium I
Major session

Friday, 25 October

10:00

Joining the dots: the relationship between substance use and other health conditions

Plenary session 3

to
Auditorium I
Plenary session

11:50

The ripple effect: International developments in the opioid market and their potential implications for European public health and security

to
Auditorium I
Major session

Psychedelics 2

to
Auditorium VI
Oral presentation session

Unravelling the nexus: understanding drug-related violence across Europe

to
Auditorium VIII
Oral presentation session

Online monitoring

to
Room 5B
Oral presentation session

Substance use and treatment needs across European prisons

to
Room 5C
Oral presentation session

How can cannabis policy goals inform the development of evaluation indicators?

to
Room 1.08
Workshop
Closed session

ECR Programme — EU research funding opportunities

to
Room 1.10
Workshop

Intimate partner violence perpetration: The ADVANCE-Digital Programme for men

to
Room 1.15
Workshop

14:20

Young people and drugs

to
Auditorium III
Oral presentation session

Addressing diverse treatment needs

to
Auditorium VI
Oral presentation session

Regulating cannabis supply policies in Europe: navigating the long road to change

to
Auditorium VIII
Oral presentation session

Future of opioid markets in Europe: Foresight approaches

to
Room 1.10
Workshop

16:00

Novel psychoactive substances and latest drug trends in Asia and Pacific countries

to
Room 1.05
Oral presentation session
Future paradigms for drug markets and drug policies?

Closing session

to
Auditorium I
Plenary session

17:40

Closing ceremony

to
Auditorium I
Plenary session

Presentations

Wednesday, 23 October

10:00

Keynote presentation

Involving people with lived experience in the development and delivery of substance use interventions: opportunities to enhance quality and outcomes

10:00 to 11:30
Auditorium I
Bronwyn Myers

Keynote presentation

How do we do more to safeguard the mental health and well-being of healthcare professionals in the substance misuse area

10:00 to 11:30
Auditorium I
Clare Gerada

11:50

Oral presentation

NIDA International Program Research Update

11:50 to 13:20
Auditorium VI
Tom Clarke

Oral presentation

Managing Benzodiazepine Dependence and High-Risk Use with Opiates: A feasibility study of a Co-produced Intervention

11:50 to 13:20
Auditorium II
Catriona Matheson

Oral presentation

Treatment of benzodiazepine withdrawal through taper dosing is most successful when it lasts less than 6 months.

11:50 to 13:20
Auditorium II
Alert Drishti

Oral presentation

Understanding the research capacity of Australian alcohol and other drug services

11:50 to 13:20
Auditorium VI
Robert Stirling

Oral presentation

Report from LX24 side event - Strengthening networks and sharing innovation in practices on research and surveillance in the drugs field

11:50 to 13:20
Auditorium VI
Vickna Kasinather
Charles Parry

Oral presentation

The effectiveness of naloxone in reversing opioid overdose: The European naloxone outcome research study (NalPORS)

11:50 to 13:20
Auditorium II
Nicola Metrebian

Oral presentation

A global perspective on the emotions associated with chemsex practice to better support the community

11:50 to 13:20
Auditorium IV
Yannick Gaudette

Short communication

A Longitudinal Evaluation of an Alcohol Related Brain Injury Specialist Residential Rehabilitation Service

11:50 to 13:20
Room 1.08
Anne Campbell

Short communication

A systematic review of the nuances of attachment, bonding and parenting for mothers in addiction recovery

11:50 to 13:20
Room 1.07
Louise McCulloch

Oral presentation

Addressing gender, diversity, and precarity: participatory research to transform addiction services in Canada

11:50 to 13:20
Auditorium IV
Karine Bertrand

Short communication

An Alcohol Strategy for the Northwest Territories

11:50 to 13:20
Room 1.08
Bryany Denning

Short communication

Barriers for treatment in alcohol use disorders (AUD) – the role of stigmatization: A consumer’s perspective

11:50 to 13:20
Room 1.08
Anja Bischof

Oral presentation

Chemsex Professional Training Program in Catalonia

11:50 to 13:20
Auditorium IV
Elena Adán Ibáñez

Short communication

Corporate political activities of the Portuguese Alcohol Industry post-COVID-19, where do we stand?

11:50 to 13:20
Room 1.08
Francisca Pulido Valente

Oral presentation

Cultural safety and telecare. A systematic scoping review and sector survey

11:50 to 13:20
Auditorium III
Rodrigo Ramalho

Oral presentation

Drug Consumption Rooms in Europe. Operational characteristics, capacities, services and its associated factors.

11:50 to 13:20
Auditorium III
Joana Moura

Short communication

Embodied Storytelling: An Accessible Approach to Re-storying in the Recovery Process

11:50 to 13:20
Room 1.07
Meghann Perry

Short communication

Emotional dysregulation as a predictor of cocaine severity and withdrawal symptoms

11:50 to 13:20
Room 1.07
Alba Palazón-Llecha

Short communication

Exploring Personal Strengths and Resources in Long-Term Substance Use Disorder Recovery: Insights from Lived Experience

11:50 to 13:20
Room 1.07
Myriam Beaulieu

Oral presentation

Lisdexamfetamine in the treatment of methamphetamine dependence, a randomised controlled trial

11:50 to 13:20
Auditorium II
Nadine Ezard

Short communication

Managed Alcohol Programmes: a realist review to identify what works, for whom, and in what circumstance

11:50 to 13:20
Room 1.08
Emma King

Oral presentation

Modelling the wider socio-economic costs of problematic opioid use in the UK

11:50 to 13:20
Auditorium VIII
George Keel

Short communication

Pragmatic case finding as a strategy to improve addressing alcohol in general practice – a mixed methods pilot study

11:50 to 13:20
Room 1.08
Torgeir Gilje Lid

Oral presentation

Prevalence of opioid dependence in Scotland, 2015-2020: results from a Multi Parameter Estimation of Prevalence model

11:50 to 13:20
Auditorium VIII
Hayley Jones

Short communication

Recovery does not stop at discharge: A qualitative evaluation of Alcohol Recovery Navigators in North East England.

11:50 to 13:20
Room 1.07
Emma-Joy Holland

Oral presentation

Substance Use, Sexual Pleasure and Recovery among gbMSM: Addressing Sexual Satisfaction in Addiction Interventions

11:50 to 13:20
Auditorium IV
Maxime Blanchette

Short communication

The effect of Individual Placement and Support on employment outcomes for individuals with substance use disorders

11:50 to 13:20
Room 1.07
Eline Borger Rognli

Oral presentation

The gendered impacts of drug stigma - a qualitative study with 10 street-involved women who use drugs in Porto

11:50 to 13:20
Auditorium IV
Cristiana Vale Pires

Short communication

The problematisation of alcohol in the Northern Territory: what did Alcohol Mandatory Treatment seek to address?

11:50 to 13:20
Room 1.08
Sarah Clifford

Oral presentation

The role of physical activity in preventing relapse: the perception of participants

11:50 to 13:20
Auditorium III
Florence Piché

Short communication

The role of specialist substance use and addiction treatment in building recovery capital

11:50 to 13:20
Room 1.07
Florian De Meyer

Oral presentation

Twenty-one years of heroin-related mortality in Australia: Joinpoint regression analysis of trends by age and gender

11:50 to 13:20
Auditorium VIII
Amanda Roxburgh

Oral presentation

Underestimate of deaths due to specific opioids in England and Wales for a decade

11:50 to 13:20
Auditorium VIII
Shuoqi Chen

Short communication

Understanding the process of drug addiction recovery through learning from lived experience

11:50 to 13:20
Room 1.07
Thomas Martinelli

Oral presentation

User experiences of a digital intervention among individuals on opioid use disorder treatment in Kenya

11:50 to 13:20
Auditorium III
Sarah Kanana Kiburi

Short communication

“I drink less and that's no small matter”: A qualitative study of a managed alcohol program evaluation in Barcelona.

11:50 to 13:20
Room 1.08
Amaia Garrido

14:20

Oral presentation

Why is a gender perspective needed in the drug field? Insight from the latest European drugs data.

14:20 to 15:50
Auditorium VIII
Linda Montanari

Short communication

Alcohol prevention: a review using Topic Modelling

14:20 to 15:50
Room 1.08
Nina Harth

Short communication

Barriers and Enablers in Disclosing Substance Use by Pregnant Women in Australian prisons

14:20 to 15:50
Room 1.06
So Bi Kim

Short communication

Cannabis and mental health in Germany: a baseline estimation pre legalization

14:20 to 15:50
Room 1.08
Eva-Maria Krowartz

Short communication

Digital Invisibility: Presence of Substance Use Disorder Treatment Programs for Women in the Caribbean

14:20 to 15:50
Room 1.06
Rocio Suarez Ordoñez

Short communication

Evaluation of heroin-assisted treatment in Norway: Protocol for a mixed methods study

14:20 to 15:50
Room 1.08
Lars Henrik Myklebust

Oral presentation

Gender Compression Over Time in Measures of Cannabis Use by Age and Cohort in the United States

14:20 to 15:50
Auditorium VIII
Michael Vuolo

Short communication

In favor or against the codependency concept: A narrative review of arguments in scientific literature

14:20 to 15:50
Room 1.08
Alexis Beaulieu-Thibodeau

Oral presentation

Judge Demographics and Their Impact on Sentencing of Drug Crimes

14:20 to 15:50
Auditorium IV
Sarah Henry Davis

Oral presentation

Leximetric analysis of drug laws and evaluation of outcomes: cross-country analyses approach

14:20 to 15:50
Auditorium IV
Carla Rossi

Oral presentation

Navigating the Shift: Understanding the Dynamics of Cannabis Use in Germany Amidst Legalization Prospects

14:20 to 15:50
Auditorium IV
Sally Olderbak

Short communication

Phosphatidylethanol as a screening tool for alcohol consumption during pregnancy

14:20 to 15:50
Room 1.06
Margareeta Häkkinen

Short communication

Prevalence and trends of ethanol and drugs among arrested drivers in Norway in the period 2013-2023

14:20 to 15:50
Room 1.08
Ragnhild Jamt

Oral presentation

Smoking and nicotine use behaviours among women of reproductive age: a ten-year population study in England

14:20 to 15:50
Auditorium VIII
Sharon Cox

Oral presentation

The effects of legislative measures for 3-MMC in the Netherlands on drug sample composition and self-reported effects.

14:20 to 15:50
Auditorium IV
Pieter Oomen

Short communication

The important role of social connectedness in the alcohol use of women aged 50 to 62 years.

14:20 to 15:50
Room 1.06
Grainne Clarke

Oral presentation

The perspective of transgender and non-binary people on their substance use trajectories and resilience processes

14:20 to 15:50
Auditorium VIII
Abdelhakim Missoum

Short communication

The relationship between cannabis and tobacco use - a systematic review and meta-analysis

14:20 to 15:50
Room 1.08
Tesfa Mekonen

Short communication

Tuning In for Chemistry: Setting up a multi-instrument mobile drug-checking lab at a 7-day psychedelic music festival

14:20 to 15:50
Room 1.08
Daniel Martins

Short communication

Utilization of pharmacological treatment for alcohol use disorder in pregnancy in the total Swedish population

14:20 to 15:50
Room 1.06
Sara Wallhed Finn

16:00

Oral presentation

Canada synthetic opioids situation

16:00 to 17:30
Auditorium VIII
Pam Kent

Oral presentation

Emerging drug trends – what are the issues and how can we strengthen preparedness

16:00 to 17:30
Auditorium VIII
Paul Griffiths

Oral presentation

The U.S. international perspective including the Global Coalition

16:00 to 17:30
Auditorium VIII
Charlotte Sisson

Oral presentation

US experience with synthetic drugs

16:00 to 17:30
Auditorium VIII
Christopher M. Jones

Oral presentation

"Boxing Clever Cork saved my life": an evaluation of an Irish early addiction recovery initiative

16:00 to 17:30
Auditorium III
Rebekah Brennan

Oral presentation

A Safer Downtown for All: Including People Who Use Drugs in the Solutions to Social Disorder

16:00 to 17:30
Auditorium III
Rob Boyd

Short communication

Accessibility, local socioeconomic disadvantage and expenditure on electronic gambling machines

16:00 to 17:30
Room 1.07
Jani Selin

Short communication

Associations between mental health and substance use in higher education students in Germany – a cross-sectional study

16:00 to 17:30
Room 1.08
Robert Hrynyschyn

Short communication

Barriers and facilitators for accessing HCV care in PWID: a qualitative study using an intersectional approach

16:00 to 17:30
Room 1.08
Ilhame Anwar

Short communication

Barriers and facilitators to accessing drug treatment services for people who use drugs in Oman: a qualitative study.

16:00 to 17:30
Room 1.08

Oral presentation

Building Capacity For Future Evaluation of Residential Treatment for People Experiencing Homelessness and Addiction

16:00 to 17:30
Auditorium III
Ed Addison

Oral presentation

Challenges and support needs among persons with a migration background who use drugs in four metropolitan cities

16:00 to 17:30
Room 5C
Wouter Vanderplasschen

Oral presentation

Drug use and (non-)use of addiction treatment by women in French Guyana: gender and migration effects

16:00 to 17:30
Room 5C
Estelle Filipe

Short communication

Envisioning youth-dedicated overdose prevention and drug consumption sites in Canada and Portugal

16:00 to 17:30
Room 1.08
Kali-olt Sedgemore

Short communication

Exploring the biopsychosocial needs of ageing heroin users in treatment in Malta: implications for service provision

16:00 to 17:30
Room 1.08
Anna Grech

Short communication

Extended hours of video game play and negative physical symptoms and pain

16:00 to 17:30
Room 1.07
Janni Leung

Short communication

Financial hardship and gambling severity: a population-based study in Finland

16:00 to 17:30
Room 1.07
Tanja Grönroos

Short communication

Harmful types of gambling: Changes and emerging trends in longitudinal helpline data

16:00 to 17:30
Room 1.07
Håkan Wall

Short communication

Late relapse among ex-smokers using e-cigarettes following a quit attempt: a prospective one-year follow-up study

16:00 to 17:30
Room 1.08
Lion Shahab

Short communication

Mental health in people with hazardous cannabis and alcohol use - insights from a study of regulated cannabis sales

16:00 to 17:30
Room 1.08
Maximilian Buschner

Oral presentation

Migrants in the criminal justice system: A qualitative understanding of the role of substance use in their lives

16:00 to 17:30
Room 5C
Marjolein De Pau

Short communication

Online Gambling Companies’ Interpretation of Duty of Care and its Implication for Responsibilisation of Gambling Related Harm

16:00 to 17:30
Room 1.07
Maria Persson

Oral presentation

Psychoactive Substance Use Among Russian Migrants Relocated to Georgia Following the 2022 Ukrainian Invasion

16:00 to 17:30
Room 5C
David Otiashvili

Oral presentation

Refugees & drug use in Belgium: A national study on drug-related intervention needs in the reception setting (DrugInt)

16:00 to 17:30
Room 5C
Charlotte de Kock

Short communication

Religiosity and gambling - moderating role of reflective thinking: A Polish-Georgian Study

16:00 to 17:30
Room 1.07
Rafał Bartczuk

Short communication

Substance induced psychosis among persons with concurrent mental health and substance use disorders under pandemic

16:00 to 17:30
Room 1.08
Jørgen G. Bramness

Short communication

Suicide by people in contact with drug and alcohol services: a national study 2021 to 2022

16:00 to 17:30
Room 1.08
Patrick Horgan

Oral presentation

Superiority and cost-effectiveness of Individual Placement and Support for people with alcohol and drug dependence

16:00 to 17:30
Auditorium III
John Marsden

Short communication

What increases the risk of problem gambling in adolescents? Findings from the Greek arm of the ESPAD study

16:00 to 17:30
Room 1.07
Alexandra Primeti

17:50

Oral presentation

Application of the International Standards for the Treatment of Drug Use Disorders and the Key Quality Standards for service appraisal

17:50 to 19:20
Auditorium II
Anja Busse

Oral presentation

International Consortium on Quality in Substance Use Disorders Treatment

17:50 to 19:20
Auditorium II
Rita Notarandrea

Oral presentation

Insights from the Recipient of the first ICQ Quality Seal Award

17:50 to 19:20
Auditorium II
Michael W. Johnson

Oral presentation

PIQAT: Program for International Quality Assurance in Treatment

17:50 to 19:20
Auditorium II
Mariano Montenegro

Oral presentation

A Collaborative Approach to New Drug Identification in an Emerging Drug Early Warning System

17:50 to 19:20
Auditorium III
Donna Papsun

Oral presentation

Achieving universal health coverage of opioid agonist treatment in Norway: a cost-utility analysis

17:50 to 19:20
Room 5B
Prayash Chaudhary

Oral presentation

AN IMPLEMENTATION SCIENCE EVALUATION OF SCOTLAND’S FIRST HEROIN ASSISTED TREATMENT (HAT) FACILITY

17:50 to 19:20
Room 5B
Andrew McAuley

Short communication

Being Seen and Heard: Exploring the Relational Dimension of Heroin Assisted Treatment in Norway.

17:50 to 19:20
Room 1.06
Vegard Haukland

Short communication

Death after residential treatment for opioid use disorder among people using fentanyl

17:50 to 19:20
Room 1.06
Jan Gryczynski

Oral presentation

Emergence of semi-synthetic cannabinoids in Europe – a perspective from the European Union Early Warning System

17:50 to 19:20
Auditorium III
Rachel Christie

Short communication

Global utilization trends for weekly/monthly injectable buprenorphine (CAM2038) in the treatment of Opioid Use Disorder

17:50 to 19:20
Room 1.06
Michael Frost

Oral presentation

Heavy drinking among ‘sober generation’ youth: a longitudinal study

17:50 to 19:20
Room 5C
Marit Edland-Gryt

Oral presentation

Medical use of psychedelic substances: EUDA's monitoring of key developments

17:50 to 19:20
Auditorium VIII
Alexander Söderholm

Oral presentation

Motivations for cocaine use: relation with drug use patterns, risks and how this informs prevention

17:50 to 19:20
Room 5C
Eva Blomme

Oral presentation

Motivations underlying co-use of benzodiazepines and opioids in the UK: a qualitative study

17:50 to 19:20
Room 5C
Gaby Vojt

Short communication

Oxycodone and Morphine use in hospitals and primary healthcare in Norway 2010-2021

17:50 to 19:20
Room 1.06
Eirik Haarr

Oral presentation

Reduced health care utilization after entering opioid agonist treatment; change in mental and somatic health domains

17:50 to 19:20
Room 5B
Thomas Clausen

Oral presentation

Route-Dependent Subjective Effects of Medical Heroin in HAT: Implications for Treatment Trajectories

17:50 to 19:20
Room 5B
Silvana De Pirro

Oral presentation

Self-therapeutic use of psilocybin, MDMA and ketamine among Dutch nightlife attendees.

17:50 to 19:20
Auditorium VIII
Frederiek Schutten

Oral presentation

Synthetic cathinones in drug-related deaths – an alarming issue or triviality?

17:50 to 19:20
Auditorium III
Ilkka Ojanperä

Oral presentation

The U.S. Psilocybin Landscape: Policy Evolution and Nationally Representative Insights

17:50 to 19:20
Auditorium VIII
Beau Kilmer

Oral presentation

Trends in GHB use and harms in Australia

17:50 to 19:20
Auditorium III
Rachel Sutherland

Short communication

Trends in the detection and co-detection of drugs in a population attending opioid agonist treatment: 2010 to 2020

17:50 to 19:20
Room 1.06
Gráinne Cousins

Oral presentation

‘Russian Roulette’: how do people who co-use benzodiazepines and opioids experience the absence of harm reduction?

17:50 to 19:20
Room 5C
Hannah Poulter

19:30

Discussion

Why are we not doing better at reducing drug-related deaths?

19:30 to 20:30
Auditorium I
Thomas Clausen
Marie Jauffret-Roustide
Keith Humphreys
Paul Dietze
Katri Abel-Ollo

Thursday, 24 October

10:00

Keynote presentation

How will new strategies for addressing synthetic opioid and stimulant addiction impact the clinical and research agenda?

10:00 to 11:30
Auditorium I
Adam Bisaga

Keynote presentation

Will psychedelics play a more important role in the treatment of mental health problems in the future?

10:00 to 11:30
Auditorium I
Gabriella Gobbi

11:50

Oral presentation

A Global Perspective on Treatment Service Provision for Opioid Use Disorders

11:50 to 13:20
Auditorium III
Arash Khojasteh Zonoozi

Oral presentation

A Holistic Multi-Disciplinary Healthcare Pathway for Older Men who use Anabolic Androgenic Steroids

11:50 to 13:20
Room 1.08
Evelyn Hearne

Short communication

A scoping review of mass media interventions intended to reduce stigma towards people who use drugs

11:50 to 13:20
Auditorium VII
Adam Holland

Oral presentation

A wastewater-based approach to monitor shifting trends in illicit drugs consumption in Switzerland

11:50 to 13:20
Room 5A
Livia Andrani

Oral presentation

Cannabis policy and practice in Finland: from social media discussions to citizens initiatives

11:50 to 13:20
Room 1.08
Aleksi Hupli

Discussion

Challenges, threats, and opportunities in addiction publishing today

11:50 to 13:20
Room 1.05
John Marsden
Matilda Hellman
Anees Bahji
Bryon Adinoff

Short communication

Changes in the use of non-prescribed hydromorphone and unregulated opioids use in Vancouver, Canada, 2018-2022

11:50 to 13:20
Auditorium VII
Kanna Hayashi

Short communication

Definition of public amenity in drug consumption room literature: A scoping review

11:50 to 13:20
Auditorium VII
Bianca Whiteside

Oral presentation

Drugs and climate change: knowledge gaps in monitoring environmental impacts of drugs

11:50 to 13:20
Room 1.08
Tim Surmont

Short communication

Enhancing Harm Reduction: A Qualitative Evaluation of Athens' Drug Consumption Room

11:50 to 13:20
Auditorium VII
Benjamin Scher

Oral presentation

European Hair Drug Analisys Network – A pioneer study to investigate the use of NPS and NSO

11:50 to 13:20
Room 5A
Elisa Fornero

Oral presentation

Health-related quality of life trajectories of patients in heroin-assisted treatment

11:50 to 13:20
Auditorium III
Francesca Melis

Oral presentation

Key challenges for alcohol epidemiology and alcohol control policy evaluation

11:50 to 13:20
Auditorium VI
Jürgen Rehm

Oral presentation

Legally grey? Drug checking perspectives in the CEECA region

11:50 to 13:20
Auditorium VI
Eliza Kurcevič

Oral presentation

Opioid disorder treatment outcomes — the OPTIMUS international consensus on evidence-based and patient-centred care

11:50 to 13:20
Auditorium III
Lucas Wiessing

Short communication

Overdoses in the drug consumption room in Oslo: route of administration matters!

11:50 to 13:20
Auditorium VII
Desiree Eide

Oral presentation

Perceptions of family physicians in Istanbul on e-cigarettes as smoking cessation aids

11:50 to 13:20
Room 1.08
Melis Selamoglu

Oral presentation

Public health for whom? Unpacking the assumptions and silences in Canada's public health approach to substance use.

11:50 to 13:20
Auditorium VI
Sophie Henderson

Short communication

Reasons for (non-)using a drug consumption room: the point of view of drug users.

11:50 to 13:20
Auditorium VII
Sanda Samitca

Short communication

Safe Inhalation Pipe Provision Study: Intervening to improve policy and practice for people who use crack in England.

11:50 to 13:20
Auditorium VII
Magdalena Harris

Oral presentation

Synthesis of multisource data for the development of an advanced dashboard to monitor illicit drugs markets

11:50 to 13:20
Room 5A
Pierre Esseiva

Oral presentation

The Costs and Harms of Substance Use in Canada: Key Trends from 2007 to 2022

11:50 to 13:20
Auditorium VI
Pam Kent

Short communication

The Value of Peer Research: A Peer Perspective

11:50 to 13:20
Auditorium VII
Christos Anastasiou

Oral presentation

Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022

11:50 to 13:20
Auditorium III
Michael Farrell

Oral presentation

What can Portugal do to prevent be caught off guard again in the drug domain?

11:50 to 13:20
Room 5A
Alcina Correia

14:20

Oral presentation

Practical overview of management including naloxone dosing. Illustration with cases related to potent synthetic opioids, St Thomas’ hospital, 2023.

14:20 to 15:50
Auditorium VIII
Paul Dargan

Oral presentation

Looking Ahead: Future Priorities for Cannabis Research, Public Education, and Prevention

14:20 to 15:50
Auditorium IV
Shea Wood

Oral presentation

Overview of the Cannabis Act and Cannabis Regulations

14:20 to 15:50
Auditorium IV
Robert Gabrys

Oral presentation

Post-mortem analytical findings and characteristics of the nitazene-related deaths cases, Finland, 2023

14:20 to 15:50
Auditorium VIII
Kriikku Pirkko

Oral presentation

A Review of the Public Health and Safety Impacts of Cannabis of Legalization and Key Recommendations

14:20 to 15:50
Auditorium IV
Justine Renard

Oral presentation

Acute drug toxicity outbreak with nitazenes involved in prison setting and the community, La Réunion, France, June-July 2023

14:20 to 15:50
Auditorium VIII
Joris Guyon

Oral presentation

Acute nitazene-toxicity presentations to hospital emergency services, Dublin, Ireland, November 2023 outbreak

14:20 to 15:50
Auditorium VIII
Adrian Moughty

Oral presentation

A mixed methods systematic review of interventions for women in the perinatal period, who are dependent on drugs

14:20 to 15:50
Room 5B
Emma Smith

Oral presentation

Cannabis use disorder and the brain: The role of cross-cultural differences in cannabis attitudes

14:20 to 15:50
Auditorium III
Janna Cousijn

Oral presentation

Differential effects of left and right insula inhibition on craving and cognitive control in regular smokers

14:20 to 15:50
Auditorium III
Mieke Schulte

Oral presentation

Female-specific trends and treatment needs for substance use disorder among homeless and at-risk females

14:20 to 15:50
Room 1.08
Anne Marie Carew

Oral presentation

Gender and drugs: Experiences of stigma/toxicophobia and narcofeminist narratives

14:20 to 15:50
Room 1.08
Marie Jauffret-Roustide

Oral presentation

Peripheral endocannabinoids and related lipids in individuals with chronic non-medical prescription opioid use

14:20 to 15:50
Auditorium III
Sara Kroll

Oral presentation

Pregnancy-related hospitalisation among women who inject drugs in Melbourne, Australia

14:20 to 15:50
Room 5B
Ashleigh Stewart

Oral presentation

The care pathways of women who use drugs in the perinatal period. Findings of a qualitative, longitudinal study

14:20 to 15:50
Room 5B
Polly Radcliffe

Oral presentation

The genetic etiology of cannabis use: from twin models to genome-wide association studies and beyond

14:20 to 15:50
Auditorium III
Karin J. H. Verweij

Oral presentation

The perinatal period as a window of opportunity for change and recovery? A study of mothers and relatives' accounts

14:20 to 15:50
Room 5B
Sarah Vandewalle

Oral presentation

Unveiling the Nexus of Addiction, Violence, and Risk: Generational Patterns in Female Populations

14:20 to 15:50
Room 1.08
Sabrina Molinaro

Oral presentation

Vulnerabilities and agencies of women who use and sell drugs in Bordeaux and Montréal

14:20 to 15:50
Room 1.08
Sarah Perrin

16:00

Oral presentation

Psychosocial Care

16:00 to 17:30
Room 5C
Paul O'Brien

Oral presentation

ACCS complexity of care provision

16:00 to 17:30
Room 5C
Jacob Krzanowski

Oral presentation

The Addiction Clinical Care Suite (ACCS): service outline and 2 year outcome data

16:00 to 17:30
Room 5C
John Archer

Oral presentation

Background and establishment of the Addiction Clinical Care Suite (ACCS): a comprehensive, multi-disciplinary inpatient addiction service in London

16:00 to 17:30
Room 5C
Shantelle Quashie

Oral presentation

25 years of monitoring the Dutch cannabis market using chemical analys: trends, developments and technical discussion

16:00 to 17:30
Room 1.08
Pieter Oomen

Oral presentation

Brorphine analogues as new psychoactive substances: in vitro and in vivo pharmacological characterization

16:00 to 17:30
Auditorium III
Marthe Vandeputte

Short communication

Chronic alcohol exposure and thiamine transport in BBB in Alcohol Use Disorder

16:00 to 17:30
Room 1.06
Joana Teixeira

Oral presentation

Drug monitoring by samples seized at 2018, 2022 and 2023 BOOM festival editions

16:00 to 17:30
Room 1.08
Carla Filipa Ferreira

Short communication

Epigenetic modulation of in vitro neurodifferentiation of NG108-15 cells by the synthetic cannabinoid THJ-2201

16:00 to 17:30
Room 1.06
Catarina Pereira-Teixeira

Short communication

Exploring the bioavailability and hepatotoxic effects of psychoactive chloro-cathinones.

16:00 to 17:30
Room 1.06
Rita Pacheco

Short communication

Human-relevant concentrations of synthetic cannabinoid THJ-2201 alter mitochondrial dynamics during neurodifferentiation

16:00 to 17:30
Room 1.06
Rui Filipe Malheiro

Oral presentation

In vitro cannabinoid activity-based screening of seized plant materials: a future-proof harm reduction strategy?

16:00 to 17:30
Auditorium III
Axelle Timmermamn

Short communication

Introducing the Theory of Preloading: A Cognitive-Behavioural Motivational Model

16:00 to 17:30
Room 1.06
Jacob Sorbello

Oral presentation

LECUCA: Analysis of Brazil's largest open drug scene using time-series cross-sectional survey data

16:00 to 17:30
Room 1.08
Clarice Madruga

Oral presentation

Neurotoxicity of synthetic cathinones: Can metabolism play a role?

16:00 to 17:30
Auditorium III
Alexandra Antunes

Oral presentation

Pharmacology of 30 semisynthetic cannabinoids – and why details matter when assessing the harm potential of seized drugs

16:00 to 17:30
Auditorium III
Christophe Stove

Short communication

Synthetic cannabinoids ADB-FUBINACA and THJ-2201 dysregulate osteogenesis-related mechanisms in vitro

16:00 to 17:30
Room 1.06
João Pedro Silva

Oral presentation

Trends in illicit and licit substance use across Spain – A comprehensive three-year wastewater-based epidemiology study.

16:00 to 17:30
Room 1.08
José Benito Quintana

Short communication

Unraveling the genetic architecture of smoking: pathways of genetic risk through addiction and socioeconomics

16:00 to 17:30
Room 1.06
Adrià Túnez

17:50

Oral presentation

Acute drug-toxicity presentations involving polydrug use to Euro-DEN Plus sentinel hospitals in Europe from 2014 to 2022

17:50 to 19:20
Room 5B
Peter Heudtlass

Oral presentation

Cocaine use on the rise – are politicians and city level services prepared for the emerging trend of crack cocaine?

17:50 to 19:20
Auditorium III
Else Kristin Utne Berg

Oral presentation

Data collection on acute drug toxicity using the Euro-DEN plus model in countries bordering the European Union

17:50 to 19:20
Room 5B
Thomas Néfau

Discussion

How can the voices of people with lived experience, clients and communities impacted by drug use better inform clinical practice, research and the policy agenda?

17:50 to 18:50
Auditorium I
Tony Duffin
Luís Mendão
Joanne Neale
Elizabeth (Elza) Berk
Judy Chang

Oral presentation

Inpatient admissions in people with opioid dependence: a portuguese population-based observational retrospective study

17:50 to 19:20
Room 5B
José Miguel Paupério

Oral presentation

It is time to take nitrous oxide seriously

17:50 to 19:20
Room 5C
Julaine Allan

Oral presentation

Misuse of psychoactive medicines and its harmful consequences in Portugal

17:50 to 19:20
Auditorium VIII
Ana Araújo

Oral presentation

Nangs in Australia: Investigating nitrous oxide use among people who regularly use MDMA and/or other illicit stimulants

17:50 to 19:20
Room 5C
Jodie Grigg

Oral presentation

New challenges for outpatient care: trends from twenty years of monitoring treatment demand in the city of Hamburg

17:50 to 19:20
Room 5C
Marcus Martens

Oral presentation

Non-Fatal Overdose: A Decade-Long Analysis of Inner-City Hospitals and Nationwide Trends Across Ireland (2011-2021)

17:50 to 19:20
Room 5B
Jo-Hanna Ivers

Oral presentation

Population aging and apparent decline in initiation of injecting drug use in Australia

17:50 to 19:20
Room 5C
Olivia Price

Oral presentation

Responding to the identification of nitazenes within the illicit diazepam market

17:50 to 19:20
Auditorium III
Josie Smith

Discussion

ScaleUp: Options for scalable psychosocial and pharmacological treatment of stimulant use disorder

17:50 to 19:20
Room 1.08
Anja Busse
Didier Jutras-Aswad
Ivan Montoya
Nadine Ezard
Adam Bisaga

Oral presentation

Socioeconomic risk factors for long-term prescription opioid use: A national registry-linkage study

17:50 to 19:20
Auditorium VIII
Ingvild Odsbu

Oral presentation

Understanding Drug Use in a Dutch Prison: A Call for Improved Research and Care and Lessons learned

17:50 to 19:20
Auditorium III
Daan van der Gouwe

Oral presentation

Using intensive longitudinal data to investigate predictors of cannabis and opioid use among patients with chronic pain

17:50 to 19:20
Auditorium VIII
Johannes Thrul

Oral presentation

Words vs. strands: Does the concordance of self-reported and hair-analyzed substance use of young adults change over time?

17:50 to 19:20
Auditorium III
Clarissa Janousch

18:50

Keynote presentation

EUDA presentation

18:50 to 19:20
Auditorium I
Alexis Goosdeel

Friday, 25 October

16:00

Oral presentation

Experiences of building a Prompt Response Network for emerging drugs of concern in Australia

16:00 to 17:30
Room 1.05
Brendan Clifford

Oral presentation

Emerging Drug trends in Japan: rethinking prevention strategies

16:00 to 17:30
Room 1.05
Hironobu Fujiwara

Oral presentation

Exploring Novel Psychoactive Substances Among Kazakhstan's Youth: A Focus on Emerging Trends and Risks

16:00 to 17:30
Room 1.05
Mariya Prilutskaya

Oral presentation

The case of Kratom: from traditional medical to recreational use

16:00 to 17:30
Room 1.05
Vicknasingam Balasingam

Keynote presentation

WHO work to assessing needs and availability of training programmes for professionals in the substance misuse field

16:00 to 17:40
Auditorium I
Carina Ferreira-Borges

Keynote presentation

Amsterdam’s quest for sensible drug regulation

16:00 to 17:40
Auditorium I
Femke Halsema

Keynote presentation

Understanding the potential future global impacts of the revolution in synthetic drug production and use

16:00 to 17:50
Auditorium I
Vanda Felbab-Brown

10:00

Keynote presentation

How well do our existing models of behavioural addictions fit with our understanding of substance use disorders?

10:00 to 11:30
Auditorium I
Marc Potenza

Keynote presentation

Understanding the relationships between substance use disorders and other health outcomes, with a special focus on cancer

10:00 to 11:30
Auditorium I
Robyn Burton

11:50

Oral presentation

Situation in Afghanistan: Opium cultivation and heroin production

11:50 to 13:20
Auditorium I
Angela Me

Oral presentation

Substance use patterns among young homicide offenders in Finland 2002-2022

11:50 to 13:20
Auditorium VIII
Anna Raeste

Oral presentation

Homicides committed by criminal groups involved in Swedish drug distribution

11:50 to 13:20
Auditorium VIII
Kim Moeller

Oral presentation

Opium and heroin production in Southeast Asia

11:50 to 13:20
Auditorium I
Bryce Pardo

Oral presentation

An exploration of drug market, gun violence and sociodemographic patterns in Stockholm Sweden and the prediction of gun violence

11:50 to 13:20
Auditorium VIII
Mia-Maria Magnusson

Oral presentation

Implications of heroin shortages in Europe: the emergence of synthetic opioids

11:50 to 13:20
Auditorium I
Joanna Morais

Oral presentation

Revisiting Goldstein: A New Framework for Understanding Drug-Related Violence in a Globalised Era

11:50 to 13:20
Auditorium VIII
Marieke Liem

Oral presentation

The evolving situation with nitazenes in Ireland

11:50 to 13:20
Auditorium I
Eamon Keenan

Oral presentation

An online survey of cannabis users and ex-users in Ireland

11:50 to 13:20
Room 5B
Philip James

Oral presentation

Current perspectives on the research and medical use of psychedelic drugs for alcohol addiction treatment

11:50 to 13:20
Auditorium VI
Anton Gomez-Escolar

Oral presentation

Do Self-Report Drug Use Surveys Produce the Same Results in Print and Online Mode? Findings from a Dual Mode Survey.

11:50 to 13:20
Room 5B
Stelios Stylianou

Oral presentation

Drug use in French prisons. Results of the ESSPRI survey

11:50 to 13:20
Room 5C
Caroline Protais

Oral presentation

Online approach and characteristics of the hidden population with substance use disorder that doesn’t reach treatment

11:50 to 13:20
Room 5B
Ilias Paraskevopoulos

Oral presentation

Prison-based treatment needs for people with a history of substance use disorder: A nationwide cohort study

11:50 to 13:20
Room 5C
Birgitte Thylstrup

Oral presentation

Psychedelic therapy in the treatment of addiction: the past, present and future

11:50 to 13:20
Auditorium VI
Rayyan Zafar

Oral presentation

Substance use and psychological states in imprisoned population in Greece—Key findings from a recent nationwide survey

11:50 to 13:20
Room 5C
Ioulia Bafi

Oral presentation

The old kid in the block: Unpacking signals of increased availability and use of ketamine

11:50 to 13:20
Auditorium VI
Rita Jorge

Oral presentation

The Pharmacological Management of Ketamine Use Disorder: A Systematic Review

11:50 to 13:20
Auditorium VI
Emmert Roberts

Discussion

The ripple effect: International developments in the opioid market and their potential implications for European public health and security

11:50 to 13:20
Auditorium I
Steve Taylor

Oral presentation

What can we learn about poly-drug use among frequent cannabis users? results from the European Web Survey on Drugs

11:50 to 13:20
Room 5B
Davide Fortin

14:20

Oral presentation

Update on the situation in the Netherlands (tbc)

14:20 to 15:50
Auditorium VIII
Margriet Van Laar

Oral presentation

Cannabis law reform in Switzerland: purpose, opportunities, and risks of local pilot projects

14:20 to 15:50
Auditorium VIII
Frank Zobel

Oral presentation

Issues of transport, driving safety & intoxication for opioid agonist treatment clients in New South Wales, Australia

14:20 to 15:50
Auditorium VI
Daniel Winter

Oral presentation

Cannabis law reform in Germany: a rocky road to a partial legalisation

14:20 to 15:50
Auditorium VIII
Jakob Manthey

Oral presentation

Physical conditions and associated health service utilization among individuals with substance-related disorders

14:20 to 15:50
Auditorium VI
Christophe Huỳnh

Oral presentation

Cannabis law reform in Luxembourg: first observations after its change among recreational cannabis users and non-users

14:20 to 15:50
Auditorium VIII
Nadine Berndt

Oral presentation

The effect of substance use disorders on vaccine uptake, acceptance, and adherence: a global systematic review

14:20 to 15:50
Auditorium VI
Eva Maria Havelka

Oral presentation

Out of treatment drug and alcohol users in England: ‘Unmet Treatment Need’?

14:20 to 15:50
Auditorium VI
Charlie Lloyd

Oral presentation

Does Variation in Local Policy Mediate the Impact of Legal Cannabis Markets on Adolescent Cannabis Use?

14:20 to 15:50
Auditorium III
Rosalie Liccardo Pacula

Oral presentation

Drug an ALcohol Related Intoxication Among Young Adolecents in Palestine

14:20 to 15:50
Auditorium III
Saed Bilbaisi

Oral presentation

New processes of normalisation? Understanding changes in young people's drug use in the UK.

14:20 to 15:50
Auditorium III
Harry Sumnall

Oral presentation

The (cost-)effectiveness of contingency management for cannabis use disorder in youth: A randomized controlled trial

14:20 to 15:50
Auditorium III
Eva Garssen
View all tracks
MENU

EUROPE POC